Evidence map›Paper›PMID 42144523›Full record

ReviewCancer treatment and research2026

Metabolic Cross Talk in the Tumor Microenvironment.

Chinmay Das, Somya Ranjan Dash, Biswajit Das, Subhajit Chatterjee, Tithi Parija

Abstract readReview
PubMed Publisher
In one paragraph

Review in Cancer treatment and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Chinmay DasSchool of Biotechnology, Kalinga Institute of Industrial Technology Deemed to be University, Bhubaneswar, Odisha, India.
Somya Ranjan DashCancer Metastasis & Therapeutics Lab, Department of Biological Sciences, Indian Institute of Science Education and Research (IISER), Berhampur, Odisha, India.
Biswajit DasDepartment of Molecular, Cell and Developmental Biology, University of California, Santa Cruz, CA, USA.
Subhajit ChatterjeeLaboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD, USA.
Tithi ParijaSchool of Biotechnology, Kalinga Institute of Industrial Technology Deemed to be University, Bhubaneswar, Odisha, India. tithi.parija@kiitbiotech.ac.in.ORCID https://orcid.org/0000-0002-4547-079X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The tumor microenvironment (TME) is a dynamic network of diverse cellular and noncellular components that interact with malignant cells to influence cancer progression, immune evasion, metastasis, and the development of therapeutic resistance. The major constituents of the TME include malignant cells, immune cells, stromal cells, endothelial cells (ECs), pericytes, adipocytes, nerve cells, and the extracellular matrix (ECM). Findings revealed that a dynamic metabolic crosstalk occurs continuously within the tumor niche, leading to metabolic rewiring in the tumor resident cells that supports cancer progression under nutrient deprivation, hypoxia, and acidosis conditions in TME. This chapter provides a comprehensive overview of various types of metabolic interactions between malignant cells and the diverse cellular components of the TME, including autocrine, paracrine, juxtacrine, and endocrine-like communication, and highlights the role of key metabolites involved in this type of communication. Thus, the interplay between malignant and tumor-resident cells emphasizes their metabolic interactions that promote drug resistance. Additionally, the chapter explores the molecular mechanisms and signaling pathways triggered by this exchange of metabolites. The chapter also explores the molecular mechanisms and signaling pathways triggered by metabolite exchange and clarifies how dysregulated metabolic reprogramming contributes to cancer progression and drug resistance. Therefore, understanding these complex metabolic interactions within the tumor niche provides critical insights for developing novel therapeutic approaches that target the metabolic vulnerabilities of the malignant cells.

Indexed as

NeoplasmsTumor MicroenvironmentAnimalsHumansMetabolic ReprogrammingSignal Transductionand endocrine signalingAutocrineDrug resistanceImmune infiltrationJuxtacrineMetabolic crosstalkMetabolic reprogrammingMetabolic vulnerabilitiesParacrineStromal and immune cellsTumor microenvironment (TME)Tumor progression

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.